Adding Arginine Tags to a Cyclic Appetite-Suppressing Peptide Made It Work Better in Mice | Research

The takeaway

Attaching three arginine amino acids to a cyclic melanocortin peptide enhanced its appetite-suppressing effect in mice beyond what lab tests predicted, suggesting a new design strategy for obesity drugs.

3 arginines
Adding three extracyclic arginine residues to a cyclic melanocortin peptide enhanced appetite suppression in mice via both subcutaneous and intrathecal routes

What the researchers found

Adding three arginine amino acids to the outside of a cyclic melanocortin peptide made it more effective at suppressing food intake in mice, both when injected into the spinal canal (intrathecally) and under the skin (subcutaneously). The modified peptide maintained or increased potency at melanocortin receptors in cell-based assays, and the in vivo appetite suppression exceeded what lab tests predicted.

This arginine-addition strategy was inspired by setmelanotide, an FDA-approved melanocortin drug for genetic obesity that also uses an extracyclic arginine critical for its activity.

Why it matters

Melanocortin peptide drugs like setmelanotide treat rare genetic obesity by activating MC4R, but designing more effective versions is an active area of research. This study shows that adding arginine residues — a simple structural modification — can enhance a cyclic peptide's real-world effectiveness beyond what lab tests suggest. This disconnect between in vitro and in vivo results is a critical insight for future melanocortin drug design.

The numbers in context

3 extracyclic Arg residues · 0–3 Arg variants tested · Equipotent or increased in vitro agonist potency · Greater food intake reduction in vivo (IT and SC routes) · 3 FDA-approved melanocortin drugs referenced

How the study worked

Researchers synthesized macrocyclic melanocortin peptide agonists with 0 to 3 extracyclic arginine residues attached via a branching lysine. In vitro activity was tested at mouse melanocortin receptors. Two compounds — the parent macrocycle and the 3-arginine derivative — were then tested in vivo in mice for food intake reduction via intrathecal and subcutaneous injection.

Who was studied

Mouse melanocortin receptor assays (in vitro) and mouse feeding studies (in vivo)

What this study cannot tell us

This is an animal study using mice — human pharmacokinetics and efficacy could differ substantially. The specific food intake reduction data points were not provided in the abstract. The mechanism by which extracyclic arginines enhance in vivo efficacy (possibly cell penetration or bioavailability) was not conclusively determined. Only a limited number of variants were tested in vivo.

How to read the evidence

This is preliminary preclinical evidence from in vitro receptor assays and mouse feeding studies. While the results are clear and mechanistically interesting, translation to human efficacy requires extensive further testing.

When this study was published

Published in 2024, this study represents cutting-edge peptide chemistry research building on the success of FDA-approved melanocortin drugs like setmelanotide.

The bigger picture

This study advances the science of macrocyclic peptide design — an area gaining traction because cyclic peptides are more stable and drug-like than linear ones. The finding that adding cell-penetrating arginine residues improves in vivo efficacy beyond what in vitro assays predict challenges how melanocortin drugs are currently screened. It also connects to setmelanotide, showing that features of approved drugs can guide next-generation peptide engineering.

Questions still open

Do the extracyclic arginines enhance efficacy by improving cell penetration, bioavailability, or some other mechanism?
Could this arginine-addition strategy be applied to other cyclic peptide drug classes beyond melanocortins?
How would the 3-arginine derivative perform in primate models closer to human physiology?

Common questions

What are melanocortin peptides and why do they matter for obesity?

Melanocortin peptides activate receptors in the brain (especially MC4R) that regulate appetite and energy balance. Three melanocortin peptide drugs are already FDA-approved, including setmelanotide for rare genetic obesity. Researchers are engineering improved versions that could treat more common forms of obesity.

Why did adding arginines make the peptide work better in mice but not in lab tests?

The arginines may help the peptide penetrate cell membranes or improve its bioavailability in living animals — effects that don't show up in standard receptor binding assays. This suggests that current lab screening methods may miss important properties that matter in the body, and that drug candidates should be evaluated in vivo earlier in development.

Read the original research

Incorporation of Three Extracyclic Arginine Residues into a Melanocortin Macrocyclic Agonist (c[Pro-His-DPhe-Arg-Trp-Dap-Lys(Arg-Arg-Arg-Ac)-DPro]) Decreases Food Intake When Administered Intrathecally or Subcutaneously Compared to a Macrocyclic Ligand Lacking Extracyclic Arginine Residues (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro)].

ACS pharmacology & translational science, 7(4), 1114-1125

View on PubMed ↗Publisher’s paper ↗

Citation

Ericson, Mark D; Freeman, Katie T; Larson, Courtney M; Bouchard, Jacob L; John, Kristen; Lunzer, Mary M; Koerperich, Zoe M; Haskell-Luevano, Carrie. (2024). Incorporation of Three Extracyclic Arginine Residues into a Melanocortin Macrocyclic Agonist (c[Pro-His-DPhe-Arg-Trp-Dap-Lys(Arg-Arg-Arg-Ac)-DPro]) Decreases Food Intake When Administered Intrathecally or Subcutaneously Compared to a Macrocyclic Ligand Lacking Extracyclic Arginine Residues (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro)].. ACS pharmacology & translational science, 7(4), 1114-1125. https://doi.org/10.1021/acsptsci.4c00011